>>
<<
ISO 10993-23:2021(en)
ISO - Cover page
Foreword
Introduction
1 Scope
2 Normative references
3 Terms and definitions
4 General principles — Step-wise approach
5 Pre-test considerations
 5.1 General
 5.2 Types of material
  5.2.1 Initial considerations
  5.2.2 Ceramics, metals and alloys
  5.2.3 Polymers
  5.2.4 Biologically derived materials
 5.3 Information on chemical composition
  5.3.1 General
  5.3.2 Existing data sources
6 In vitro irritation tests
 6.1 General
 6.2 In vitro reconstructed human epidermis model
  6.2.1 Test system — Reconstructed human epidermis model
  6.2.2 Principle of the method
  6.2.3 Prediction model
 6.3 Materials
  6.3.1 Reconstructed human epidermis models — Product description
  6.3.2 Preparation of medical device extracts
 6.4 Methods
  6.4.1 General
  6.4.2 Test procedure
  6.4.3 Media and end point solutions
  6.4.4 Test sample and control preparation
 6.5 Considerations for test performance
  6.5.1 Receipt of the reconstructed human epidermis tissues
  6.5.2 Preparation and pre-incubation
 6.6 Application of the test sample and rinsing
  6.6.1 General
  6.6.2 Preparation
  6.6.3 Test extract and controls exposure
 6.7 MTT test for determination of RhE tissue viability after the exposure period
  6.7.1 MTT incubation and Isopropanol extraction
  6.7.2 Absorbance measurements
 6.8 Test acceptance criteria
 6.9 Data calculation steps
  6.9.1 General
  6.9.2 Isopropanol background control for OD in RhE assay
  6.9.3 Negative DPBS or PBS treated controls
  6.9.4 Positive control
  6.9.5 Tested extract and VC samples (TTs)
 6.10 Data interpretation — Prediction model
 6.11 Method documentation sheet
 6.12 Test report
7 In vivo irritation tests
 7.1 General
 7.2 Animal irritation test by skin exposure
  7.2.1 Principle
  7.2.2 Test materials
  7.2.3 Animals and husbandry
  7.2.4 Test procedure
  7.2.5 Observation of animals
  7.2.6 Evaluation of results
  7.2.7 Test report
 7.3 Animal irritation test by intracutaneous (intradermal) administration
  7.3.1 Introduction
  7.3.2 Exclusion from test
  7.3.3 Test sample
  7.3.4 Animals and husbandry
  7.3.5 Test procedure
  7.3.6 Observation of animals
  7.3.7 Evaluation of results
  7.3.8 Test report
8 Human skin irritation test
 8.1 Introduction
 8.2 Initial considerations
Annex A (normative) Preparation of materials for irritation testing
Annex B (informative) Test method check list for in vitro irritation testing using reconstructed human epidermis models
Annex C (informative) Example of method documentation sheet for reconstructed human epidermis models
Annex D (normative) Special irritation tests
Annex E (normative) Human skin irritation test
Annex F (informative) Background information on irritation tests
Bibliography
30mm
20mm
15mm
15mm
10mm
17mm

International

Standard

ISO 10993-23
Biological evaluation of medical devices —
Part 23:
Tests for irritation
Évaluation biologique des dispositifs médicaux —
Partie 23: Essais d'irritation
Reference number
ISO 10993-23:2021(en)
First edition
2021-01
30mm
20mm
15mm
15mm
10mm
17mm
30mm
20mm
15mm
15mm
10mm
17mm

ContentsPage

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.
The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).
Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).
Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.
For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.
This document was prepared by Technical Committee ISO/TC 194, Biological and clinical evaluation of medical devices, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 206, Biological and clinical evaluation of medical devices, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).
A list of all parts in the ISO 10993 series can be found on the ISO website.
Any feedback or questions on this document should be directed to the user’s national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

This document assesses possible contact hazards from medical devices, which can produce irritation.
Some materials that are included in medical devices have been tested, and their skin or mucosal irritation potential has been demonstrated. Other materials and their chemical components have not been tested and can induce adverse effects when in contact with human tissue. The manufacturer is thus obliged to evaluate each device for potential adverse effects prior to marketing.
The irritation potential of a medical device or its components can be predicted either by an in vivo animal irritation test or by an in vitro irritation test if qualified for use with medical devices.
ISO 10993-2 describes animal welfare aspects for performing animal studies for the biological evaluation of medical devices thereby also emphasizing the 3R’s for replacement, reduction, and refinement of animal studies. This document describes tests to determine the irritancy of medical devices, materials or their extracts either by in vitro tests or in vivo tests. In vitro tests have preference over in vivo tests when appropriately validated and providing equally relevant information to that obtained from in vivo tests (see ISO 10993-1 and ISO 10993-2).
Traditionally, tests in small animals have been performed prior to testing on humans to help predict human responses. More recently, in vitro tests as well as human tests have been added as adjuncts or alternatives. For skin irritation testing of neat chemicals in vitro tests were developed using reconstructed human epidermis (RhE) models[31]. The method was adapted for detection of irritant chemicals in medical device extracts. The results of a large round robin study that tested two types of RhE models showed that these models can also be used to detect the presence of irritant chemicals extracted from polymeric materials [polyvinylchloride (PVC) and silicone] commonly used in the manufacture of medical devices[6]. This method was found to be equally sensitive in the detection of low concentrations of some strong irritant compounds when compared to the human patch testing and intracutaneous rabbit test[14]. Therefore, a stepwise approach for irritant testing can start with the in vitro RhE model.
The developed and validated RhE models are appropriate to predict skin tissue irritation response. It is recommended to explore the use of other alternative in vitro models to assess the irritation potential for mucosal or eye epithelial applications.
It is intended that, for regulatory submission, these studies be conducted using GLP or ISO/IEC 17025 as applicable to the respective country and comply with regulations related to animal welfare. Statistical analysis of data is recommended and can be used whenever appropriate.
This document is intended for use by professionals, appropriately qualified by training and experience, who are able to interpret its requirements and judge the outcomes of the evaluation for each medical device, taking into consideration all the factors relevant to the device, its intended use and the current knowledge of the medical device provided by review of the scientific literature and previous clinical experience.
The tests included in this document are important tools for the development of safe products, provided that they are executed and interpreted by trained personnel.
This document is based on numerous standards and guidelines, including OECD Test Guidelines (TG), U.S. Pharmacopoeia[40] and the European Pharmacopoeia[39]. It is intended to be the basic document for the selection and conduct of tests enabling evaluation of irritation responses relevant to the safety of medical materials and devices.
Instructions are given in normative Annex A for the preparation of materials specifically in relation to the above tests. In normative Annex D several special in vivo irritation tests are described for application of medical devices in areas other than skin. In addition, normative Annex E provides information for conducting human skin irritation testing.
30mm
20mm
15mm
15mm
10mm
17mm

International StandardISO 10993-23:2021(en)
Biological evaluation of medical devices —
Part 23:
Tests for irritation

1Scope

This document specifies the procedure for the assessment of medical devices and their constituent materials with regard to their potential to produce irritation. The tests are designed to predict and classify the irritation potential of medical devices, materials or their extracts according to ISO 10993-1 and ISO 10993-2.
This document includes:
—
pre-test considerations for irritation, including in silico and in vitro methods for dermal exposure;
—
details of in vitro and in vivo irritation test procedures;
—
key factors for the interpretation of the results.

2Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies
ISO 10993-1, Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process
ISO 10993-2, Biological evaluation of medical devices — Part 2: Animal welfare requirements
ISO 10993-9, Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products
ISO 10993-12, Biological evaluation of medical devices — Part 12: Sample preparation and reference materials
ISO 10993-13, Biological evaluation of medical devices — Part 13: Identification and quantification of degradation products from polymeric medical devices
ISO 10993-14, Biological evaluation of medical devices — Part 14: Identification and quantification of degradation products from ceramics
ISO 10993-15, Biological evaluation of medical devices — Part 15: Identification and quantification of degradation products from metals and alloys
ISO 10993-18, Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process
ISO 14155, Clinical investigation of medical devices for human subjects — Good clinical practice
OECD 404, Acute Dermal Irritation/Corrosion
OECD 439, In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method

3Terms and definitions

For the purposes of this document, the following terms and definitions apply.
ISO and IEC maintain terminological databases for use in standardization at the following addresses:
—
ISO Online browsing platform: available at https://www.iso.org/obp
—
IEC Electropedia: available at http://www.electropedia.org/
3.1
blank
solution prepared in the same way as the sample measuring solution but so that it does not contain the analyte to be determined
[SOURCE: ISO 10136‑1:1993, 3.8, modified — the term has been changed from "blank test solution" to "blank".]
3.2
dose
dosage
amount of test sample (3.14) administered (e.g. mass, volume) expressed per unit of body weight or surface area
Note 1 to entry: The terms are often used interchangeably (more commonly dosage).
3.3
erythema
reddening of the skin or mucous membrane
3.4
eschar
scab or discoloured slough of skin
3.5
extract
liquid or suspension that results from exposing a test or control material to an extraction vehicle (3.16) under controlled conditions
3.6
irritant
agent that produces irritation (3.7)
3.7
irritation
localized non-specific inflammatory response to single, repeated or continuous application of a substance/material
Note 1 to entry: Skin irritation is a reversible reaction and is mainly characterized by local erythema (3.3) (redness) and swelling [oedema (3.9)] of the skin.
3.8
necrosis
cell death as a direct result of irreversible changes caused by injury or disease
Note 1 to entry: Tissue repair will occur either resulting in complete functional restoration or resulting in scar formation.
3.9
negative control
well-characterized material or substance that, when evaluated by a specific test method, demonstrates the suitability of the procedure to yield a reproducible, appropriately negative, non-reactive or minimal response in the test system
Note 1 to entry: In practice, negative controls (NC) include blanks (3.1), vehicles (3.16)/solvents and reference materials.
3.10
oedema
swelling due to abnormal infiltration of fluid into the tissue
3.11
positive control
well-characterized material or substance that, when evaluated by a specific test method, demonstrates the suitability of the test system to yield a reproducible, appropriately positive or reactive response in the test system
3.12
skin corrosion
production of irreversible damage to the skin, manifested as visible necrosis (3.8) through the epidermis and into the dermis, following application of a test sample (3.14)
EXAMPLE        The action of a compound, chemical or a test sample resulting in ulceration of skin (see 3.15).
3.13
test material
material, device, device portion or component thereof that is sampled for biological or chemical testing
3.14
test sample
material, device, device portion, component, extract (3.5) or portion thereof that is subjected to biological or chemical testing or evaluation
3.15
ulceration
open sore representing loss of superficial tissue
3.16
vehicle
liquid used to moisten, dilute, suspend, extract (3.5) or dissolve the test substance/material
3.17
vehicle control
extraction vehicle (3.16) not containing the test material (3.13), retained in a vessel identical to that which holds the test material and subjected to identical conditions to which the test material is subjected during its extraction
Note 1 to entry: The purpose of the vehicle control (VC) is to evaluate possible confounding effects due to the extraction vessel, the vehicle and the extraction process.
30mm
20mm
15mm
15mm
10mm
17mm

Bibliography
[1]
ISO 9394:2012, Ophthalmic optics — Contact lenses and contact lens care products — Determination of biocompatibility by ocular study with rabbit eyes
[2]
Agner T. Noninvasive measuring methods for the investigation of irritant patch test reactions. A study of patients with hand eczema, atopic dermatitis and controls. Acta Derm. Venereol. Suppl. (Stockh.). 1992, 173 pp. 1–26
[3]
Alépée N., Tornier C., Robert C., Amsellem C., Roux M.-H., Doucet O., & et al A catch-up validation study on reconstructed human epidermis (SkinEthicTM RHE) for full replacement of the Draize skin irritation test. Toxicol. In Vitro. 2010, 24 pp. 257–266
[4]
Casas J.W., Lewerenz G.M., Rankin E.A., Willoughby J.A., Blakeman L.C., McKim J.M., & et al In Vitro Human Skin Irritation Test for Evaluation of Medical Device Extracts. Toxicol. In Vitro. 2013, 27 pp. 2175–2183
[5]
Coleman K.P., Grailer T.P., McNamara L.R., Rollins B.L., Christiano N.J., Kandárová H., & et al Preparation of irritant polymer samples for an in vitro round robin study. Toxicol. In Vitro. 2018, 50 pp. 401–406.
[6]
De Jong W.H., Hoffmann S., Lee M., Kandárová H., Pellevoisin C., Haishima Y., & et al Round robin study to evaluate the reconstructed human epidermis (RhE) model as an in vitro skin irritation test for detection of irritant activity in medical device extracts. Toxicol. In Vitro. 2018, 50 pp. 439–449.
[7]
Draize J.H., Woodand G., & Calvery H.O. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 1944, 82 pp. 337–390
[8]
Draize J.H. Appraisal of the safety of chemicals in foods, drugs, and cosmetics, Austin, Texas, Association of food and drug officials of the United States, Texas State Department of Health, 1959
[9]
Faller C., Bracher M., Dami N., & Roguet R. Predictive ability of reconstructed human epidermis equivalents for the assessment of skin irritation of cosmetics. Toxicol. In Vitro. 2002, 16 pp. 557–572
[10]
Hagi-Pavli E., Williams D.M., Rowland J.L., Thornhill M., & Cruchley A.T. Characterizing the immunological effects of oral healthcare ingredients using an in vitro reconstructed human epithelial model. Food Chem. Toxicol. 2014, 74 pp. 139–148
[11]
Horita K., Tomita C., Yasoshima M., & Matsunaga K. Optimal evaluation time point for patch testing to predict skin irritation of commercial topical drugs. J. Dermatol. 2015, 42 pp. 851–860.
[12]
Kandárová H., Hayden P., Klausner M., Kubilus J., Kearney P., & Sheasgreen J. (2009): In Vitro Skin Irritation Test: Improving the Sensitivity of the EpiDerm Skin Irritation Test Protocol. ATLA 37, 671–669, 2009
[13]
Kandarova H., Willoughby J.A., De Jong W.H., Letasiova S., Milasova T., Bachelor M.A., & et al Pre-validation of an in vitro skin irritation test for medical devices using the reconstructed human tissue model EpiDerm™ Toxicol. In Vitro. 2018, 50 pp. 407–417.
[14]
Kandárová H., Bendova H., Letasiova S., Coleman K.P., De Jong W.H., & Jírova D. Evaluation of the medical devices benchmark materials in the controlled human patch testing and in the RhE in vitro skin irritation protocol. Toxicol. In Vitro. 2018, 50 pp. 433–438
[15]
Lee C.H., & Maibach H.I. The sodium lauryl sulfate model: an overview. Contact Dermat. 1995, 33 pp. 1–7
[16]
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983, 65 pp. 55–62
[17]
Olsen D.S., Lee M., & Turley A.P. Assessment of test method variables for in vitro skin irritation testing of medical device extracts. Toxicol. In Vitro. 2018, 50 pp. 426–432.
[18]
Pellevoisin C., Tornier C., Bremond C., Rollins B., Briotet D., Turley A., & et al Skin irritation of medical devices: In vitro assay with EPISKIN reconstructed human epidermis (RHE). Toxicol. Lett. 2016, 258 (S63) p. viii
[19]
Pellevoisin C., Videau C., Briotet D., Grégoire C., Tornier C., Alonso A., & et al SkinEthic™ RHE for in vitro evaluation of skin irritation of medical device extracts. Toxicol. In Vitro. 2018, 50 pp. 419–425
[20]
SOP of in vitro skin irritation of medical devices extracts with SkinEthic™ RHE. EPISKIN SA, Lyon (France), Available at https://www.episkin.com/~/media/Files/SOP-SkinEthic-RHE-Irritation-Medical-devices, 2018
[21]
In Vitro EpiDerm™ Skin Irritation Test (EPI-200-SIT). Protocol For use with MatTek Corporation’s Reconstructed Human Epidermal Model EpiDerm™ (EPI-200-SIT). MK-24-007-0023. Available at https://www.mattek.com/wp-content/uploads/Medical-Devices-Testing-Protocol-201603010.pdfhttps://www.mattek.com/wp-content/uploads/EPI-200-SIT-Skin-Irritation_MK-24-007-0023_10_02_19.pdf, 2017
[22]
Nomura Y., Lee M., Fukui C., Watanabe K., Olsen D., Turley A., Morishita Y., Kawakami T., Yuba T., Fujimaki H., Inoue K., Yoshida M., Ogawa K., & Haishima Y. Proof of concept testing of a positive reference material for in vivo and in vitro skin irritation testing. J Biomed Mater Res B Appl Biomater, 2018, 106(8) pp. 2807–2814
[23]
Scott L., Eskes C., Hoffmann S., Adriaens E., Alepée N., Bufo M., & et al A proposed eye irritation testing strategy to reduce and replace in vivo studies using Bottom-Up and Top-Down approaches. Toxicol. In Vitro. 2010, 24 pp. 1–9
[24]
Wahlberg J.E., & Wahlberg E.N. Quantification of skin blood flow at patch test sites. Contact Dermat. 1987, 17 pp. 229–233
[25]
Wahlberg J.E., & Mailbach H.I. Nonanoic acid irritation — A positive control at routine patch testing? Contact Dermat. 1980, 6 pp. 128–130
[26]
Walters R.M., Khanna P., Hamilton M., Mays D.A., & Telofski L. Human Cumulative Irritation Tests of Common Preservatives Used in Personal Care Products: A Retrospective Analysis of Over 45 000 Subjects. Toxicol. Sci. 2015, 148 pp. 101–107
[27]
York M., Griffiths H.A., Whittle E., & et al Evaluation of a human patch test for the identification and classification of skin irritation potential, Contact Dermatitis, 1996, 34, pp. 204–212.
[28]
European Chemical Industry Ecology and Toxicology Centre Eye irritation testing, Monograph 11, Brussels, Belgium, 1988
[29]
Organization for Economic Cooperation and Development (OECD) Guidelines for testing of chemicals No. 405, Acute eye irritation/corrosion. OECD Publications, Paris, 2017
[30]
Organization for Economic Cooperation and Development (OECD) Guidelines for testing of chemicals. No. 430, In Vitro Skin Corrosion: Transcutaneous Electrical Resistance Test (TER). OECD Publications, Paris, 2015
[31]
Organization for Economic Cooperation and Development (OECD) Test No. 431: In vitro skin corrosion: reconstructed human epidermis (RHE) test method, OECD Guidelines for the Testing of Chemicals, Section 4, Éditions OCDE, Paris, 2019
[32]
Organization for Economic Cooperation and Development (OECD) Guidelines for testing of chemicals. No. 437. Bovine Corneal Opacity and Permeability Test Method for Identifying i) Chemicals Inducing Serious Eye Damage and ii) Chemicals Not Requiring Classification for Eye Irritation or Serious Eye Damage. OECD Publications, 2020
[33]
Organization for Economic Cooperation and Development (OECD) Test No. 438: Isolated Chicken Eye Test Method for Identifying i) Chemicals Inducing Serious Eye Damage and ii) Chemicals Not Requiring Classification for Eye Irritation or Serious Eye Damage, OECD Guidelines for the Testing of Chemicals, Section 4, Éditions OCDE, Paris, 2018
[34]
Organization for Economic Cooperation and Development (OECD) Guidelines for testing of chemicals. No. 460. Fluorescein Leakage Test Method for Identifying Ocular Corrosives and Severe Irritants. OECD Publications, Paris, 2017
[35]
Organization for Economic Cooperation and Development (OECD) Test No. 491: Short Time Exposure In Vitro Test Method for Identifying i) Chemicals Inducing Serious Eye Damage and ii) Chemicals Not Requiring Classification for Eye Irritation or Serious Eye Damage, OECD Guidelines for the Testing of Chemicals, Section 4, Éditions OCDE, Paris, 2020.
[36]
Organization for Economic Cooperation and Development (OECD) Test No. 492: Reconstructed human Cornea-like Epithelium (RhCE) test method for identifying chemicals not requiring classification and labelling for eye irritation or serious eye damage, OECD Guidelines for the Testing of Chemicals, Section 4, Éditions OCDE, Paris, 2019
[37]
Organization for Economic Cooperation and Development (OECD) Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment, OECD Series on Testing and Assessment, No. 34, OECD Publishing, Paris, 2005
[38]
British Pharmacopoeia Commission. British Pharmacopoeia 2016. London: TSO; 2016.
[39]
European Pharmacopoeia , 10th Edition , European Pharmacopoeia, Council of Europe, B.P. 907, F-67029 Strasbourg, France, 2019
[40]
United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeial Convention; 2020.
[41]
Commission Regulation (EU) 2019/1390 of 31 July 2019 amending, for the purpose of its adaptation to technical progress, the Annex to Regulation (EC) No 440/2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Text with EEA relevance) OJ L 247, 26.9.2019
30mm
20mm
15mm
15mm
10mm
17mm
ICS 11.100.20
Price based on 60 pages
iso.org